Medical Prognosis Institute And TD2 Join In Strategic Collaboration To Provide Drug Developers A Unique Multi Biomarker Direct Path To Drug Approval
4/3/2014 10:35:59 AM
HOERSHOLM, Denmark and SCOTTSDALE, Ariz., April 3, 2014 (GLOBE NEWSWIRE) -- Medical Prognosis Institute A/S (MPI) - a Danish company and Translational Drug Development LLC (TD2) based in Scottsdale, Arizona, today announced a strategic collaboration offering a proprietary service that defines which initial clinical indication would most likely lead to drug approval. "This technology can dramatically increase the probability of early clinical success" said Dr. Stephen Gately, CEO for TD2.
Help employers find you! Check out all the jobs and post your resume.
comments powered by